Atlas of Genetics and Cytogenetics in Oncology and Haematology

Home   Genes   Leukemias   Solid Tumors   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

X Y 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 NA

t(1;14)(q21;q32) FCGR2B/IGH

Written2005-02Jacques Boyer
Laboratoire d' hématologie, CH du MANS, France

(Note : for Links provided by Atlas : click)


Atlas_Id 1341

Clinics and Pathology

Disease Follicular lymphoma in one CD10+ case, but without a t(14;18)(q32;q21), bcl2 negative, and with a t(1;14)(q21;q32); follicular lymphoma with FCGR2B rearrangement and dup(1)(q21q25)in another case .
Epidemiology These two cases with FCGR2B rearrangement were found among a panel of 76 non Hodgkin's lymphomas.
Prognosis May be associated with tumor progression.


Cytogenetics Morphological One case with 46, XX, t(1;14)(q21;q32), t(8;9)(q24;q13); progression to a diffuse large cells lymphoma with a complexe caryotype. An another case with FCGR2B rearrangement in a follicular lymphoma: the karyotype was complexe with dup(1)(q21q25), t(14;18)(q32;q21).

Genes involved and Proteins

Gene NameFCGR2B (Fc fragment of IgG, low affinity IIb, receptor (CD32))
Location 1q23.3
Gene NameIGH (Immunoglobulin Heavy)
Location 14q32.33

Result of the chromosomal anomaly

Hybrid gene
Description The translocation juxtapose the 5' switch region og IGHG2 to a region upstream of FCGR2B in the der(1) chromosome.FCGR2B is deregulated by this translocation and FCGR2B b2 mRNA isoform is overexpressed.
Fusion Protein
Note No fusion protein.
Oncogenesis It is possible that alteration in the b2/b1 mRNA isoforms ratio in B-cells may promote B cell survival. This anomaly is bcl2 deregulation-independant because FCGR2B has been shown to be a tumor-enhancing factor in non lymphoid cells in murine in vivo and in vitro models. Deregulation of FCGR2B expression can be considered as a second event which may impart additional growth advantage to the bcl2 deregulated B-cells.

To be noted

Additional cases are needed to delineate the epidemiology of this rare entity:
you are welcome to submit a paper to our new Case Report section.


The IgG Fc receptor, FcgammaRIIB, is a target for deregulation by chromosomal translocation in malignant lymphoma.
Callanan MB, Le Baccon P, Mossuz P, Duley S, Bastard C, Hamoudi R, Dyer MJ, Klobeck G, Rimokh R, Sotto JJ, Leroux D
Proceedings of the National Academy of Sciences of the United States of America. 2000 ; 97 (1) : 309-314.
PMID 10618414
Deregulation of FCGR2B expression by 1q21 rearrangements in follicular lymphomas.
Chen W, Palanisamy N, Schmidt H, Teruya-Feldstein J, Jhanwar SC, Zelenetz AD, Houldsworth J, Chaganti RS
Oncogene. 2001 ; 20 (52) : 7686-7693.
PMID 11753646
Non-Hodgkin's Lymphoma: Molecular Features of B Cell Lymphoma.
Macintyre E, Willerford D, Morris SW
Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program. 2000 : 180-204.
PMID 11701542


This paper should be referenced as such :
Boyer, J
t(1;14)(q21;q32) FCGR2B/IGH
Atlas Genet Cytogenet Oncol Haematol. 2005;9(2):151-151.
Free journal version : [ pdf ]   [ DOI ]
On line version :

Translocations implicated (Data extracted from papers in the Atlas)

 t(1;14)(q21;q32) FCGR2B/IGH

External links

Mitelman databaset(1;14)(q21;q32) [Case List]    t(1;14)(q21;q32) [Transloc-MCList] FCGR2B/IGH [Fusion-MCList]
arrayMap (UZH-SIB Zurich)[select an item]
REVIEW articlesautomatic search in PubMed
Last year articlesautomatic search in PubMed
All articlesautomatic search in PubMed

© Atlas of Genetics and Cytogenetics in Oncology and Haematology
indexed on : Mon Aug 12 16:59:43 CEST 2019

Home   Genes   Leukemias   Solid Tumors   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

For comments and suggestions or contributions, please contact us